{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T01:48:25Z","timestamp":1773798505042,"version":"3.50.1"},"reference-count":44,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacy"],"abstract":"<jats:p>(1) Background: Hyperphosphatemia is correlated with an increased rate of mortality and morbidity due to cardiovascular diseases in chronic kidney disease (CKD) patients. It can be improved by restricting dietary intake of phosphate and oral phosphate binders, such as lanthanum carbonate and sevelamer carbonate. (2) Objective: To evaluate the clinical efficacy of sevelamer carbonate in comparison to lanthanum carbonate as phosphate binders for the treatment of hyperphosphatemia in CKD patients. (3) Methods: A randomized control comparative clinical study was conducted for one year on 150 CKD patients associated with hyperphosphatemia, divided into two groups, i.e., Group 1 (n = 75) treated with sevelamer carbonate 800 mg thrice daily and Group 2 (n = 75) treated with lanthanum carbonate 500 mg thrice daily. The patients were assessed at the time of enrollment in the study, after three months and after six months from baseline for different parameters, i.e., complete blood count, liver function tests, renal function tests, electrolytes, and serum phosphate level. (4) Results: 150 CKD patients aged 51\u201360 participated in the study. The mean age of patients was 54 \u00b1 4.6 years, and males (55.71%) were more common than females (44.29%). Hypertension was the common comorbidity in both groups with chronic kidney disease. After six months of treatment, the mean serum phosphate level was significantly decreased from 8.31 \u00b1 0.09 mg\/dL to 5.11 \u00b1 0.18 (38%) in Group 1 and from 8.79 \u00b1 0.28 mg\/dl to 4.02 \u00b1 0.12 (54%; p &lt; 0.05) in Group 2, respectively. In both groups, no significant difference was found in other parameters such as parathyroid hormone, calcium, uric acid, LFT, RFT, CBC, etc. (5) Conclusion: Lanthanum carbonate is more efficacious in lowering serum phosphate concentrations and effectively managing hyperphosphatemia as compared to sevelamer carbonate.<\/jats:p>","DOI":"10.3390\/pharmacy11010027","type":"journal-article","created":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T02:21:12Z","timestamp":1675304472000},"page":"27","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy of Lanthanum Carbonate and Sevelamer Carbonate as Phosphate Binders in Chronic Kidney Disease\u2014A Comparative Clinical Study"],"prefix":"10.3390","volume":"11","author":[{"given":"Parminder","family":"Nain","sequence":"first","affiliation":[{"name":"CT Institute of Pharmaceutical Sciences, Jalandhar 144020, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Narendra","family":"Nayak","sequence":"additional","affiliation":[{"name":"Department of Microbiology, St. Matthew\u2019s University School of Medicine, Georgetown P.O. Box 30992, Cayman Islands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9258-2823","authenticated-orcid":false,"given":"Mary C.","family":"Maj","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, St. George\u2019s University School of Medicine, St. George\u2019s, Grenada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohit Kumar","family":"Singh","sequence":"additional","affiliation":[{"name":"MM College of Pharmacy, Maharishi Markandeshwar University, Ambala 133207, Haryana, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaspreet","family":"Kaur","sequence":"additional","affiliation":[{"name":"CT Institute of Pharmaceutical Sciences, Jalandhar 144020, Punjab, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Medical Student Research Institute, Department of Clinical Medicine, American University of Antigua, St. John\u2019s, Antigua and Barbuda"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4180-5983","authenticated-orcid":false,"given":"Sabyasachi","family":"Maity","sequence":"additional","affiliation":[{"name":"Department of Physiology, Neuroscience and Behavioral Sciences, St. George\u2019s University School of Medicine, St. George\u2019s, Grenada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reetuparna","family":"Nath","sequence":"additional","affiliation":[{"name":"Department of Education Service, St. George\u2019s University, St. George\u2019s, Grenada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9903-8716","authenticated-orcid":false,"given":"Robert H.","family":"Hilgers","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, St. Matthew\u2019s University School of Medicine, Georgetown P.O. Box 30992, Cayman Islands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shreya","family":"Nauhria","sequence":"additional","affiliation":[{"name":"Department of Psychology, University of Leicester, Leicester LE1 7RH, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samal","family":"Nauhria","sequence":"additional","affiliation":[{"name":"Department of Pathology, St. Matthew\u2019s University School of Medicine, Georgetown P.O. Box 30992, Cayman Islands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"358985","DOI":"10.1155\/2013\/358985","article-title":"Effect of different stages of chronic kidney disease and renal replacement therapies on oxidant-antioxidant balance in uremic patients","volume":"2013","author":"Tbahriti","year":"2013","journal-title":"Biochem. Res. Int."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: A meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1007\/s11606-010-1523-6","article-title":"Primary care management of chronic kidney disease","volume":"26","author":"Allen","year":"2011","journal-title":"J. Gen. Intern. Med."},{"key":"ref_4","unstructured":"GBD Chronic Kidney Disease Collaboration (2020). Global, regional, and national burden of chronic kidney disease, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet, 395, 709\u2013733."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1016\/S0140-6736(14)61601-9","article-title":"Worldwide access to treatment for end-stage kidney disease: A systematic review","volume":"385","author":"Liyanage","year":"2015","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Ke, C., Liang, J., Liu, M., Liu, S., and Wang, C. (2022). Burden of chronic kidney disease and its risk-attributable burden in 137 low-and middle-income countries, 1990\u20132019: Results from the global burden of disease study 2019. BMC Nephrol., 23.","DOI":"10.1186\/s12882-021-02597-3"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.34067\/KID.0003982020","article-title":"Global Dialysis Perspective: India","volume":"1","author":"Bharati","year":"2020","journal-title":"Kidney360"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/ckj\/sfab149","article-title":"The Indian Chronic Kidney Disease (ICKD) study: Baseline characteristics","volume":"15","author":"Kumar","year":"2022","journal-title":"Clin. Kidney J."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Rajapurkar, M.M., John, G.T., Kirpalani, A.L., Abraham, G., Agarwal, S.K., Almeida, A.F., Gang, S., Gupta, A., Modi, G., and Pahari, D. (2012). What do we know about chronic kidney disease in India: First report of the Indian CKD registry. BMC Nephrol., 13.","DOI":"10.1186\/1471-2369-13-10"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1159\/000516286","article-title":"Phosphate Control: The Next Frontier in Dialysis Cardiovascular Mortality","volume":"11","author":"McCullough","year":"2021","journal-title":"Cardiorenal. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/1744-9987.12030","article-title":"Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients","volume":"17","author":"Taniguchi","year":"2013","journal-title":"Ther. Apher. Dial."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1517\/14740338.2014.907791","article-title":"Phosphate binders for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis: A comparison of safety profiles","volume":"13","author":"Locatelli","year":"2014","journal-title":"Expert Opin. Drug. Saf."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1093\/ndt\/gfn613","article-title":"Systematic review of the evidence underlying the association between mineral metabolism disturbances and risk of all-cause mortality, cardiovascular mortality and cardiovascular events in chronic kidney disease","volume":"24","author":"Covic","year":"2009","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ekir.2022.01.1055","article-title":"Past, Present, and Future of Phosphate Management","volume":"7","author":"Doshi","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.ekir.2021.05.012","article-title":"Phosphate Balance and CKD-Mineral Bone Disease","volume":"6","author":"Sprague","year":"2021","journal-title":"Kidney Int. Rep."},{"key":"ref_16","first-page":"1147","article-title":"Lanthanum carbonate for the control of hyperphosphatemia in chronic renal failure patients: A new oral powder formulation\u2014Safety, efficacy, and patient adherence","volume":"7","author":"Lloret","year":"2013","journal-title":"Patient Prefer. Adherence"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group, M. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/ajkd.2003.50007","article-title":"Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey","volume":"41","author":"Coresh","year":"2003","journal-title":"Am. J. Kidney Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/ki.1996.111","article-title":"Risk of developing end-stage renal disease in a cohort of mass screening","volume":"49","author":"Iseki","year":"1996","journal-title":"Kidney Int."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jsps.2015.01.009","article-title":"Hyperphosphatemia Management in Patients with Chronic Kidney Disease","volume":"24","author":"Shaman","year":"2016","journal-title":"Saudi Pharm. J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"576110","DOI":"10.3389\/fcell.2020.576110","article-title":"Disorders of Calcium and Phosphorus Metabolism and the Proteomics\/Metabolomics-Based Research","volume":"8","author":"Sun","year":"2020","journal-title":"Front Cell Dev. Biol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4103\/2230-8210.113752","article-title":"Renal phosphate handling: Physiology","volume":"17","author":"Prasad","year":"2013","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1093\/ndt\/17.7.1170","article-title":"Management of hyperphosphataemia of chronic kidney disease: Lessons from the past and future directions","volume":"17","author":"Malluche","year":"2002","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s40620-019-00689-w","article-title":"Phosphate binders in chronic kidney disease: An updated narrative review of recent data","volume":"33","author":"Floege","year":"2020","journal-title":"J. Nephrol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1681\/ASN.2011111078","article-title":"Mechanisms of anemia in CKD","volume":"23","author":"Babitt","year":"2012","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00467-017-3663-y","article-title":"Anemia in chronic kidney disease","volume":"33","author":"Atkinson","year":"2018","journal-title":"Pediatr. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of Anemia in Chronic Kidney Disease: Beyond Erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"c15","DOI":"10.1159\/000149239","article-title":"Long-term efficacy and safety profile of lanthanum carbonate: Results for up to 6 years of treatment","volume":"110","author":"Hutchison","year":"2008","journal-title":"Nephron. Clin. Pract."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Covic, A., and Rastogi, A. (2013). Hyperphosphatemia in patients with ESRD: Assessing the current evidence linking outcomes with treatment adherence. BMC Nephrol., 14.","DOI":"10.1186\/1471-2369-14-153"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1093\/ndt\/gfq682","article-title":"Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure","volume":"26","author":"Damment","year":"2011","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1111\/nep.12864","article-title":"Lanthanum carbonate: Safety data after 10 years","volume":"21","author":"Hutchison","year":"2016","journal-title":"Nephrology"},{"key":"ref_32","first-page":"207","article-title":"Use of sevelamer in chronic kidney disease: Beyond phosphorus control","volume":"35","author":"Zambrano","year":"2015","journal-title":"Nefrologia"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1440-1797.2010.01412.x","article-title":"Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial","volume":"16","author":"Toussaint","year":"2011","journal-title":"Nephrology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"178","DOI":"10.2215\/CJN.02830608","article-title":"Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: A randomized trial","volume":"4","author":"Sprague","year":"2009","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12098-012-0765-1","article-title":"Vitamin D in chronic kidney disease","volume":"79","author":"Chau","year":"2012","journal-title":"Indian J. Pediatr."},{"key":"ref_36","first-page":"428","article-title":"The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease","volume":"64","author":"Freemont","year":"2005","journal-title":"Clin. Nephrol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.2147\/TCRM.S330649","article-title":"Different Effect of Lanthanum Carbonate and Sevelamer Hydrochloride on Calcium Balance in Patients with Moderate to Advanced Chronic Kidney Disease","volume":"17","author":"Makowka","year":"2021","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000488816","article-title":"Disorders of Lipid Metabolism in Chronic Kidney Disease","volume":"46","author":"Bulbul","year":"2018","journal-title":"Blood Purif."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1681\/ASN.2005121320","article-title":"Lipids and renal disease","volume":"17","author":"Trevisan","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-981-19-0394-6_9","article-title":"Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment","volume":"1372","author":"Pan","year":"2022","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_41","first-page":"183","article-title":"Effect of sevelamer on mineral and lipid abnormalities in hemodialysis patients","volume":"19","author":"Hamida","year":"2008","journal-title":"Saudi J. Kidney Dis. Transpl."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1081\/JDI-65259","article-title":"Effect of sevelamer on dyslipidemia and chronic inflammation in maintenance hemodialysis patients","volume":"27","author":"Yamada","year":"2005","journal-title":"Ren. Fail."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1046\/j.1523-1755.2002.00459.x","article-title":"Bile acid binding to sevelamer HCl","volume":"62","author":"Braunlin","year":"2002","journal-title":"Kidney Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1681\/ASN.2020050598","article-title":"Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients","volume":"32","author":"Isaka","year":"2021","journal-title":"J. Am. Soc. Nephrol."}],"container-title":["Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/1\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:21:46Z","timestamp":1760120506000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2226-4787\/11\/1\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["pharmacy11010027"],"URL":"https:\/\/doi.org\/10.3390\/pharmacy11010027","relation":{},"ISSN":["2226-4787"],"issn-type":[{"value":"2226-4787","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}